Principal, Levine Media Group, host of The Bio Report and RARECast podcasts, award-winning journalist focused on the life sciences.
Joined October 2009
- Tweets 3,211
- Following 590
- Followers 1,725
- Likes 180
260 Photos and videos
Jun 11
David Stamler @AlterityT discusses the biology of multiple system atrophy, the company’s promising clinical results to date, and why its therapeutic approach may also have application in other neurodegenerative diseases. @globalgenes #RARECast
globalgenes.org/raredaily/ta…
1
243
Jun 10
Epigenetics may be cancer’s operating system. @k36tx is targeting a key enzyme that lets multiple myeloma grow, adapt, and resist treatment—aiming to re-sensitize tumors to existing drugs. A shift from chasing mutations to rewriting how cancer reads DNA.
thebioreport.podbean.com/e/s…
1
187
Rare disease diagnosis is at a turning point. Long-read HiFi sequencing is boosting diagnostic yield by 10–15% by capturing structural variants, epigenetics, and regulatory signals—making the case for first-line use. @PacBio CEO Christian Henry explains: globalgenes.org/raredaily/lo…
116
Most antibodies act as antagonists—but biology isn’t that simple. @MetaphoreBio's function-first platform uses live-cell data ML to design antibodies that agonize, bias, or multi-target pathways. CEO Angela Hwang explains: thebioreport.podbean.com/e/r…
1
59
May 28
FARA CEO Jen Farmer and @Solid_Bio CMO Gabriel Brooks explore the lived reality of Friedreich’s ataxia, the promise of next-generation gene therapy, and how true patient industry partnerships can shape trial design and development. @GlobalGenes
globalgenes.org/raredaily/th…
85
May 27
Cells constantly sense and respond to stress—adapting, recovering, or dying. Soley uses AI to map these responses at scale, unlocking “undruggable” targets. Soley's Yerem Yeghiazarians discusses their platform, pipeline, and first-in-class candidates.
thebioreport.podbean.com/e/m…
59
May 21
Winsights' Kasey Walsh discusses her daughter's ultra-rare genetic disorder diagnostic journey, gaps in how the patient experience informs drug development, and the Winsights data platform empowers rare disease communities to drive research priorities.
globalgenes.org/raredaily/ca…
72
May 14
Trialport's Keith Berelowitz discusses his vision for a future where clinical trials are routinely discussed alongside standard of care, the gap between clinical trial availability and patient awareness, and how the Trialport platform informs patients.
globalgenes.org/raredaily/ra…
1
101
May 13
Most cancer therapies hit 1 or 2 pathways, giving tumors a chance to adapt. Nuago CEO Robert Schickel discusses how his company is developing short RNAs to silence multiple survival genes at once—aiming for more durable tumor killing with less toxicity.
thebioreport.podbean.com/e/t…
1
70
John Wollman @KomodoHealth discusses how the company and @GeneDx are leveraging longitudinal patient data with genomic and phenotypic data to shorten rare disease diagnostic odysseys, accelerate natural hist studies, and enable better clinical decisions.
globalgenes.org/raredaily/us…
1
4
869
Crystalis CEO James Mackay discusses gout, why therapies often fail to get uric acid to target levels, and how the company’s next‑generation URAT1 inhibitor may fill the treatment gap and change daily life for patients living with moderate to severe gout.
thebioreport.podbean.com/e/a…
87
Genome sequencing is moving from last resort to frontline in rare disease care. Akash Kumar of MyOme explains what it means for treatment decisions, trial access, and the emotional burden on families searching for a diagnosis. @GlobalGenes #RARECast
globalgenes.org/raredaily/cu…
79
Apr 29
When inflammation spirals out of control, traditional drugs often don’t work. @Mesoblast's Ryoncil—the first MSC therapy in the US—targets GVHD in children. CEO @DrItescu discusses how MSCs can calm cytokine storms and what’s next for the platform.
thebioreport.podbean.com/e/a…
190
Apr 22
Most MS drugs control relapses—but don’t stop the neurodegeneration driving long-term disability. Daniel Vitt, CEO of @ImmunicInc discusses how his company’s experimental once-daily oral therapy targets both inflammation and neuronal damage.
thebioreport.podbean.com/e/s…
86
Apr 17
Jim Foote, CEO of First Ascent Biomedical, explains how combining genomics, functional assays, and AI could transform rare pediatric cancer care @GlobalGenes #RARECast
globalgenes.org/raredaily/ma…
1
65
Apr 10
Pablo Sardi @sanofi discusses the potential of the oral BTK inhibitor rilzabrutinib to treat multiple rare autoimmune conditions, and how this strategy could shift the field from treating symptoms to targeting root causes of these conditions. @GlobalGenes
globalgenes.org/raredaily/fr…
1
120
Dennis Salotti @JazzPharma discusses how use of AI for mundane but high-impact work speeds studies and improves trial-site experience and how AI can be a thinking partner, rather than a shortcut, to elevate people from doers to critical thinkers.
youtube.com/watch?v=mwwUYR0e…
1
128
For people with Lynch syndrome, cancer is often a question of when—not if. Nouscom CEO Marina Udier discusses the company’s efforts to develop cancer vaccines to stop tumors before they start by training the immune system to recognize early cancer signals.
thebioreport.podbean.com/e/i…
1
55
Alzheimer’s R&D has focused on memory loss—but for many families, the breaking point is psychosis: hallucinations and delusions that make home care impossible. @AcadiaPharma R&D head Liz Thompson discusses new approaches to treating Alzheimer’s psychosis.
thebioreport.podbean.com/e/t…
1
69
Mar 31
Here's what you may have missed in March from The Bio Report, RARECast, and Life Sciences D'n'A podcasts.
linkedin.com/pulse/editing-a…
43